Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PTK7

Gene summary for PTK7

Gene summary.

Gene information	Species	Human
	Gene symbol	PTK7
	Gene ID	5754
	Gene name	protein tyrosine kinase 7 (inactive)
	Gene Alias	CCK-4
	Cytomap	6p21.1
	Gene Type	protein-coding
	GO ID	GO:0001568
	UniProtAcc	Q13308

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5754	PTK7	P2_cSCC	Human	Skin	cSCC	2.36e-12	4.04e-01	-0.024
5754	PTK7	P4_cSCC	Human	Skin	cSCC	2.59e-14	4.34e-01	-0.00290000000000005
5754	PTK7	P10_cSCC	Human	Skin	cSCC	2.50e-43	1.03e+00	0.1017
5754	PTK7	male-WTA	Human	Thyroid	PTC	2.31e-24	2.49e-01	0.1037
5754	PTK7	PTC01	Human	Thyroid	PTC	3.19e-16	3.05e-01	0.1899
5754	PTK7	PTC03	Human	Thyroid	PTC	3.36e-05	1.62e-01	0.1784
5754	PTK7	PTC04	Human	Thyroid	PTC	5.24e-14	3.27e-01	0.1927
5754	PTK7	PTC05	Human	Thyroid	PTC	6.37e-26	7.45e-01	0.2065
5754	PTK7	PTC06	Human	Thyroid	PTC	1.50e-42	9.72e-01	0.2057
5754	PTK7	PTC07	Human	Thyroid	PTC	2.27e-35	6.30e-01	0.2044
5754	PTK7	ATC09	Human	Thyroid	ATC	1.18e-11	4.81e-01	0.2871
5754	PTK7	ATC11	Human	Thyroid	ATC	1.66e-06	5.63e-01	0.3386
5754	PTK7	ATC12	Human	Thyroid	ATC	7.31e-03	1.73e-01	0.34
5754	PTK7	ATC13	Human	Thyroid	ATC	2.97e-49	1.13e+00	0.34
5754	PTK7	ATC1	Human	Thyroid	ATC	1.61e-12	5.48e-01	0.2878
5754	PTK7	ATC2	Human	Thyroid	ATC	8.28e-06	1.82e+00	0.34
5754	PTK7	ATC3	Human	Thyroid	ATC	4.37e-09	5.82e-01	0.338
5754	PTK7	ATC4	Human	Thyroid	ATC	1.74e-06	2.18e-01	0.34
5754	PTK7	ATC5	Human	Thyroid	ATC	1.06e-66	1.22e+00	0.34

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0007163	Colorectum	AD	establishment or maintenance of cell polarity	77/3918	218/18723	5.72e-07	2.08e-05	77
GO:0042060	Colorectum	AD	wound healing	128/3918	422/18723	2.73e-06	7.89e-05	128
GO:0030111	Colorectum	AD	regulation of Wnt signaling pathway	102/3918	328/18723	8.51e-06	2.03e-04	102
GO:0016055	Colorectum	AD	Wnt signaling pathway	130/3918	444/18723	1.60e-05	3.37e-04	130
GO:0198738	Colorectum	AD	cell-cell signaling by wnt	130/3918	446/18723	2.02e-05	4.10e-04	130
GO:0031532	Colorectum	AD	actin cytoskeleton reorganization	41/3918	107/18723	2.81e-05	5.28e-04	41
GO:0010975	Colorectum	AD	regulation of neuron projection development	129/3918	445/18723	2.88e-05	5.37e-04	129
GO:0030010	Colorectum	AD	establishment of cell polarity	50/3918	143/18723	6.90e-05	1.11e-03	50
GO:0031346	Colorectum	AD	positive regulation of cell projection organization	104/3918	353/18723	8.26e-05	1.30e-03	104
GO:0060070	Colorectum	AD	canonical Wnt signaling pathway	90/3918	303/18723	1.76e-04	2.38e-03	90
GO:0060828	Colorectum	AD	regulation of canonical Wnt signaling pathway	77/3918	253/18723	2.19e-04	2.87e-03	77
GO:0045197	Colorectum	AD	establishment or maintenance of epithelial cell apical/basal polarity	20/3918	44/18723	2.26e-04	2.94e-03	20
GO:0035088	Colorectum	AD	establishment or maintenance of apical/basal cell polarity	21/3918	49/18723	4.31e-04	4.82e-03	21
GO:0061245	Colorectum	AD	establishment or maintenance of bipolar cell polarity	21/3918	49/18723	4.31e-04	4.82e-03	21
GO:0060562	Colorectum	AD	epithelial tube morphogenesis	93/3918	325/18723	5.65e-04	6.00e-03	93
GO:0014020	Colorectum	AD	primary neural tube formation	33/3918	94/18723	1.02e-03	9.50e-03	33
GO:0001841	Colorectum	AD	neural tube formation	35/3918	102/18723	1.16e-03	1.05e-02	35
GO:0030177	Colorectum	AD	positive regulation of Wnt signaling pathway	45/3918	140/18723	1.23e-03	1.09e-02	45
GO:0001843	Colorectum	AD	neural tube closure	30/3918	88/18723	2.83e-03	2.12e-02	30
GO:0060606	Colorectum	AD	tube closure	30/3918	89/18723	3.42e-03	2.49e-02	30

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PTK7

SNV

Missense_Mutation

c.1028C>A

p.Ala343Asp

p.A343D

Q13308

protein_coding

deleterious(0.01)

possibly_damaging(0.471)

TCGA-A2-A0D2-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

PTK7

SNV

Missense_Mutation

novel

c.2262N>A

p.Met754Ile

p.M754I

Q13308

protein_coding

deleterious(0.04)

benign(0.067)

TCGA-A7-A6VX-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Chemotherapy

docetaxel

PTK7

SNV

Missense_Mutation

c.2124G>T

p.Lys708Asn

p.K708N

Q13308

protein_coding

deleterious(0.04)

benign(0.082)

TCGA-A8-A0A9-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

anastrozole

PTK7

SNV

Missense_Mutation

rs374956441

c.493C>T

p.Arg165Trp

p.R165W

Q13308

protein_coding

deleterious(0)

probably_damaging(0.983)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PTK7

SNV

Missense_Mutation

novel

c.2578N>C

p.Lys860Gln

p.K860Q

Q13308

protein_coding

deleterious(0)

possibly_damaging(0.734)

TCGA-B6-A0IN-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

PTK7

SNV

Missense_Mutation

c.2317G>A

p.Glu773Lys

p.E773K

Q13308

protein_coding

deleterious(0.03)

benign(0.119)

TCGA-D8-A1JN-01

Breast

breast invasive carcinoma

Female

>=65

III/IV

Hormone Therapy

anastrozolum

PTK7

SNV

Missense_Mutation

novel

c.1769N>T

p.Ala590Val

p.A590V

Q13308

protein_coding

deleterious(0.01)

possibly_damaging(0.475)

TCGA-E9-A228-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

PTK7

SNV

Missense_Mutation

rs767634504

c.581N>T

p.Thr194Met

p.T194M

Q13308

protein_coding

deleterious(0.03)

benign(0.104)

TCGA-S3-AA14-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

PTK7

insertion

In_Frame_Ins

novel

c.2208_2209insGATCTGGGCCCAAACAGAGTCCGGTTTGGCAGACGTGGAATGTCA

p.Lys736_Arg737insAspLeuGlyProAsnArgValArgPheGlyArgArgGlyMetSer

p.K736_R737insDLGPNRVRFGRRGMS

Q13308

protein_coding

TCGA-AO-A0J9-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphamide

PTK7

insertion

Frame_Shift_Ins

novel

c.2577_2578insCTTCC

p.Lys860LeufsTer4

p.K860Lfs*4

Q13308

protein_coding

TCGA-B6-A0IN-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
5754	PTK7	DRUGGABLE GENOME, KINASE, TYROSINE KINASE, CLINICALLY ACTIONABLE		PF-06647020	COFETUZUMAB PELIDOTIN

Page: 1